Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:00:15 EDT Fri 18 Sep 2026
Enter Symbol
or Name
USA
CA



Q:IBIO - IBIO INC - https://www.ibioinc.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IBIO - Q1.11.27·1.281.01.25+0.075.92,082.52,5291,7881.25  1.3099  1.213.82  0.7708Sep 17Sep 0115 min RT 2¢

Recent Trades - Last 10 of 1788
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-01 16:30U:IBIONews ReleaseiBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference
2026-08-28 07:00U:IBIONews ReleaseiBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-08-04 07:00U:IBIONews ReleaseiBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer
2026-07-01 07:00U:IBIONews ReleaseiBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study
2026-06-02 16:01U:IBIONews ReleaseiBio to Participate in Upcoming Healthcare Investor Conferences
2026-06-02 07:00U:IBIONews ReleaseiBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
2026-05-12 16:05U:IBIONews ReleaseiBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-05-08 07:15U:IBIONews ReleaseiBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors
2026-04-08 07:00U:IBIONews ReleaseiBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
2026-03-16 16:30U:IBIONews ReleaseiBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
2026-03-09 07:00U:IBIONews ReleaseiBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
2026-02-24 07:00U:IBIONews ReleaseiBio to Participate in Upcoming Investor Conferences
2026-02-10 16:05U:IBIONews ReleaseiBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
2026-01-09 07:00U:IBIONews ReleaseiBio Announces $26 Million Private Placement
2025-11-24 16:15U:IBIONews ReleaseiBio to Participate in the 8th Annual Evercore Healthcare Conference
2025-11-12 16:01U:IBIONews ReleaseiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
2025-10-30 07:00U:IBIONews ReleaseiBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
2025-10-23 07:00U:IBIONews ReleaseiBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
2025-10-21 07:00U:IBIONews ReleaseiBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek(TM) and PEGS Europe 2025